Revolutionizing Blood Collection: Tasso’s Innovative Technology
Revolutionizing Blood Collection with Innovative Technology
In recent developments, Tasso, Inc. has taken a significant step forward in the realm of healthcare technology. This company, a leader in patient-centric blood collection solutions, has introduced its next-generation system for dried blood spot (DBS) sample collection. This system is designed to meet the needs of clinical trials and sports anti-doping testing, streamlining the process while enhancing the experience for patients.
Understanding the New Collection System
Tasso’s novel collection system combines the groundbreaking Tile™-T20 dried whole blood cartridge with the Tasso™ Mini device, allowing for precise and convenient collection of DBS samples. This innovative system represents a major improvement over traditional methods, which often rely on painful finger sticks for sample collection. Instead, Tasso’s approach not only eases the collection process but also enhances the overall experience for the patient.
Advantages Over Legacy Methods
One of the standout features of the Tile-T20 cartridge is its design tailored specifically for patient-centric blood lancets. This allows for the acquisition of four precise, volumetrically-controlled blood samples, which is essential for quantitative endpoints and drug concentration measurements. Furthermore, the cartridge is compatible with Tasso's advanced collection devices, including the FDA-cleared and CE-marked Tasso Mini and Tasso+. This technology showcases Tasso's commitment to improving clinical trial processes and patient experiences through innovative solutions.
Benefits for Clinical Trials
Ben Casavant, PhD, CEO and Co-Founder of Tasso, highlights the advantages of dried blood samples for clinical trials and remote applications. He states, “Dried blood samples offer many advantages for clinical trials and remote applications, but collection methods have long been a burden on patients.” Tasso’s next-generation systems are crafted to minimize patient discomfort while maximizing the efficiency of sample collection.
Reducing Access Challenges
Access to clinic sites can prove challenging for many patients, especially those lacking reliable transportation or residing in rural areas. This issue often leads to difficulties in recruitment and retention within clinical trials, which can ultimately delay the timelines for bringing new therapies to market. Erwin Berthier, PhD, CTO and Co-Founder of Tasso, points out that this new technology holds the potential to significantly improve the speed at which new treatments can reach those in need.
Who is Tasso?
Tasso is an emerging player in the healthcare technology arena, whose mission revolves around transforming the traditional blood collection paradigm through a patient-focused lens. The company’s innovative devices enable users to collect blood in a simple, virtually painless manner. With Tasso's technology, healthcare delivery can extend beyond conventional settings, making it accessible anytime and anywhere.
Headquartered in Seattle, Tasso operates as a privately held entity, being supported by a mix of grants, investments, and collaborations with industry leaders. This growth trajectory underscores their commitment to innovating healthcare practices and improving patient outcomes.
Frequently Asked Questions
What is Tasso's new blood collection technology?
Tasso has launched a next-generation system for dried blood spot (DBS) collection that improves the process for clinical trials and anti-doping testing.
How does Tasso's technology benefit patients?
The new technology minimizes discomfort by eliminating painful finger sticks and enables convenient, reliable blood collection.
What makes Tasso's collection system unique?
The Tile-T20 cartridge and Tasso Mini device work together to allow for precise and volumetrically-controlled sample collection.
Why is patient-centric design important in healthcare?
A patient-centric design reduces the burden of healthcare procedures, improves participation in clinical trials, and enhances overall outcomes.
How does Tasso aim to improve clinical trials?
By addressing accessibility issues and streamlining the sample collection process, Tasso aims to enhance recruitment, retention, and treatment timelines for new therapies.
About The Author
Contact Riley Hayes privately here. Or send an email with ATTN: Riley Hayes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
